

Food & Function

Linking the chemistry and physics of food with health and nutrition

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Bai, Y. Zhang, J. Fan, X. Jia, D. Li, Y. Wang, J. Zhou, Q. Yan and F. Hu, *Food Funct.*, 2020, DOI: 10.1039/C9FO02969A.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 **Immune-enhancement of oligosaccharides from *Codonopsis pilosula***
2 **on cyclophosphamide induced immunosuppression in mice**

3 Rui-Bin Bai, Ya-jie Zhang, Jing-min Fan, Xu-seng Jia, Dai Li, Yan-ping Wang, Jing
4 Zhou, Qiao Yan, Fang-Di Hu*

5
6

7 *Correspondence author

8 Fangdi Hu, Ph.D., School of Pharmacy, Lanzhou University, 199 Dong-gang Road
9 West, Lanzhou 730000, China. Tel.: +86 0931 8911865/8911895; Fax: +86 0931
10 8915686. E-mail address: hufd@lzu.edu.cn (F. Hu).

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Abstract**

40 As an important edible traditional Chinese medicine, *Codonopsis*
41 *pilosula* has good immunomodulation effects. It has been said that the
42 sweeter the *C. pilosula* tastes, the better. This study focused on *C. pilosula*
43 oligosaccharides (CPO), which is the sweetness component of *C. pilosula*.
44 CPO was obtained through systematic separation and purification (the
45 yield is 14.3%), and the effect of CPO on the immunological activities of
46 immunocompromised mice induced by cyclophosphamide (CTX) was
47 evaluated. The results showed that CPO could increase immune organs
48 indices, phagocytic index and contents of immunoglobulins, stimulate
49 proliferation of splenic lymphocytes (coordinating with ConA and LPS),
50 enhance earlap swelling of DTH reaction, promote productions of NO and
51 cytokines (IL-2 and IFN- γ) and the expressions of corresponding mRNA.
52 In addition, CPO upregulated the protein expression of phosphorylated
53 p38, phosphorylated ERK1/2 and phosphorylated JNK, which indicated
54 CPO might exert immunomodulatory activities through the MAPKs
55 signaling pathway. These findings indicated that CPO was an important
56 immunomodulatory component in *C. pilosula* and could be developed as
57 immunomodulator in medicine or functional food areas.

58

59

60

61 1. Introduction

62 Immunosuppression is a condition of long-lasting or temporary
63 immunity disfunction. Because the immune system is damaged, it makes
64 the organism more sensitive to pathogens ¹. Nowadays, many clinical
65 immunomodulators have some side effects such as levamisole and
66 *Corynebacterium parvum* bacterium². Therefore, developing safer
67 immunomodulators is important to prevent and cure immunosuppressive
68 diseases. Meanwhile, Chinese medicine has obtained a wealth of
69 theoretical and practical knowledge in its application as
70 immunomodulators, such as *ginseng*³, *Schisandra chinensis*⁴, *Glycyrrhiza*
71 *uralensis*⁵, and *Astragalus membranaceus*⁶. Modern medical research
72 have confirmed that TCM could exert immunomodulatory activities
73 through innate and acquired immunity ^{7, 8, 9}.

74 *Codonopsis pilosula*, as one kind of important TCMs, is widely used
75 to strengthen the middle warmer, invigorate spleens and nourish lungs¹⁰.
76 As medicine and food, it is very popular in China, Korea and Japan¹¹.
77 Carbohydrates are important components of *C. pilosula*. It is reported that
78 polysaccharides of *C. pilosula* could exert immunomodulatory activities by
79 provoking the proliferation of lymphocytes ¹², regulating the proportion of
80 T lymphocyte subsets^{13, 14}, promoting the secretion of cytokines ^{13, 15},
81 enhancing macrophage activity¹¹ and exhibiting complement fixing
82 activity¹⁶. At present, the reported polysaccharides from *C. pilosula* all have

83 been obtained by water-extraction and alcohol-precipitation (final
84 concentration 70~80%) and then further purified. The molecular weight
85 range is 4.84 KDa¹⁷~133.20 KDa¹⁸. The supernatant are often discarded
86 after total polysaccharides are precipitated, but oligosaccharides are
87 usually in this part. Until now, there were no reports about the
88 immunomodulatory activities of the oligosaccharides from *C.pilosula*. In
89 addition, it has been said that the sweeter the *C. pilosula* tastes, the better,
90 which has been recorded in many ancient medical writings, such as "Bai
91 Cao Jing" and "Yao Long Xiao Pin". Oligosaccharides not only taste sweet
92 but also have been proved to have various physiological activities, such as
93 stachyose¹⁹, raffinose²⁰. Therefore, we made a hypothesis that the
94 oligosaccharides were important active components in *C.pilosula*.

95 Thus, we studied the immunomodulatory effects of CPO on
96 cyclophosphamide (CTX) -treated mice through innate and adaptive
97 immunity. It proved for the first time that the oligosaccharides from
98 *C.pilosula* had good immunomodulatory activities and had potentiality to
99 develop as immunomodulator in functional foods and pharmaceuticals.

100 **2.Materials and methods**

101 *2.1 Materials*

102 Dried *Codonopsis pilosula* (Franch.) Nannf. was collected from
103 Weiyuan County (Gansu Province, China), which was identified by Prof.
104 Yin-suo Zhou, School of Pharmacy, Lanzhou University. Thymosin and

105 CTX were purchased from the First Hospital of Lanzhou University
106 (Lanzhou, Gansu Province, China). ELISA kits of interferon- γ (IFN- γ),
107 interleukin-2 (IL-2), immunoglobulin G and M (IgG and IgM) were
108 purchased from Meimian Biotechnology Co. Ltd (Nanjing, Jiangsu
109 Province, China); Indian ink, heparin sodium and ECL Western Blotting
110 Substrate were purchased from Beijing Solarbio Science & Technology
111 Co.,Ltd. (Beijing, China); Dinitrofluorobenzene was purchased from
112 Shanghai Macklin Biochemical Technology Co., Ltd. (Shanghai, China);
113 Assay kit for nitric oxide (NO) was purchased from Beyotime Institute of
114 Biotechnology (Shanghai, China); TRIzol[®] Reagent, Hifair[™] II First
115 Stand cDNA Synthesis SuperMix (11123ES60) and Hieff[™] qPCR
116 SYBR[®] Green Master Mix (11201ES60) were purchased from Yeasen
117 Biotech Co., Ltd. (Shanghai, China); Antibody SAPK/JNK, Phospho-
118 SAPK/JNK (Thr183/Tyr185), p38 MAPK, Phospho-p38 MAPK
119 (Thr180/Tyr 182), p44/p42 MAPK (Erk 1/2), Phospho-p44/42 MAPK
120 (Erk1/2) (Thr202/Tyr204) were purchased from Cell Signaling
121 Technology, Inc. (Danvers, MA, USA).

122 2.2 Extraction and purification of CPO

123 The *C. pilosula* (500 g) was crushed into powder and then defatted
124 twice with 95% EtOH for 2 h. The residue was extracted thrice with hot
125 water for 45 min each time. After filtration by defatted cotton and
126 concentration under reduced pressure, the polysaccharides were

127 precipitated with 80% ethanol (final concentration) overnight. The
128 supernatant was collected after centrifugation at 10600 g for 15 min and
129 concentrated under reduced pressure to remove ethanol. The crude product
130 of oligosaccharides was obtained after freeze-drying, named RCPO.

131 RCPO (200 mg) was dissolved in distilled water and applied to a
132 column (2.6 × 60 cm,i.d.) packed with Sephadex G-25. The column was
133 pre-equilibrated with water and eluted with distilled water. Fractions (10
134 mL/tube) were collected by a fraction collector and the content of
135 carbohydrates were analyzed through the phenol-sulfuric acid assay. ESI-
136 MS method was used to determine the molecular weight distribution of
137 CPO. The purified product of RCPO was named CPO and the production
138 steps of CPO from *C.pilosula* were shown in Fig.S1. The yield of CPO was
139 calculated as:

$$140 \quad Y(\%) = (W_{\text{oligosaccharides}} / W_{\text{powder}}) \times 100\%$$

141 Y is the yield of oligosaccharides (%), $W_{\text{oligosaccharides}}$ is the weight of
142 oligosaccharides (g), W_{powder} is the weight of *C. pilosula* (g).

143 2.3 Animals and experimental design

144 72 male kunming mice (18~22 g) were provided by the Experimental
145 Animal Center in Lanzhou University, China (the license number SCXK
146 (Gan) 2018-0002). Throughout whole experiment, the mice were reared
147 at room temperature (25 ± 2 °C), humidity (55-60%) and a 12 h light-dark
148 cycle with arbitrary water and food. All procedures were accomplished

149 according to the code of ethics of the World Medical Association and
150 approved by the Ethics Committee of School of Pharmacy, Lanzhou
151 University (approved in 20 Nov, 2018 with approve number of LZU-YX-
152 2018-11-20-1).

153 After a week of adaptive breeding, the mice were randomly divided
154 into six groups with 12 mice in each group. From the 1st day to the 20th
155 day, the daily gavage of mice was as below: normal group (NC): saline;
156 model group (MC): saline; thymosin group (XXT): 10mg/kg body weight
157 thymosin; three CPO groups (CPO50, CPO100, CPO150): 50,100 or 150
158 mg/kg body weight CPO. From the 15th day to the 18th day, all mice
159 (except NC group) were immunosuppressed by intraperitoneal (i.p.)
160 injection of 40 mg/kg body weight CTX.

161 *2.4 Calculation of immune organs indices*

162 At the end of the experiments, mice were weighed and sacrificed by
163 cervical dislocation. The thymus and spleen were excised and weighed.
164 Immune organ index was calculated according to the formula:

165 Thymus or spleen index = (weight of thymus or spleen × 1000) / (body
166 weight × 100).

167 *2.5 Determination of phagocytic index*

168 Carbon clearance assay was used to access the function of
169 macrophage according to the literature of Niu et al²¹. The mice were
170 injected with 100 μL of 4-fold dilution of Indian ink via tail vein. At the

171 point of 2 min (t_A) and 10 min (t_B), blood samples were taken from the
172 posterior orbital vein and 20 μ L sample was mixed with 2 mL 0.1%
173 Na_2CO_3 . The absorbance of each sample at 600 nm was measured (OD_A
174 for t_A and OD_B for t_B). The phagocytic index (α) was calculated as below:

$$175 \quad K = (\lg\text{OD}_A - \lg\text{OD}_B) / (t_B - t_A)$$

$$176 \quad \text{Phagocytic index } \alpha = K^{(1/3)} \times W_B / (W_L + W_S)$$

177 Where W_B , W_S and W_L are body weight, liver weight and spleen weight,
178 respectively.

179 *2.6 Determination of splenic lymphocytes proliferation*

180 As described by Zhang et al¹³, the splenic lymphocytes were seeded
181 in a 96-well plate (5×10^6 cell/mL) with ConA (20 μ g/mL) or LPS (40
182 μ g/mL). After 72 h cultured at 37 °C in 5% CO_2 , 20 μ L of 5 mg/mL MTT
183 was added to each well and incubated for another 4 h. After discarding the
184 supernatant, DMSO (150 μ L) was added into each well. The absorbance at
185 570 nm was measured.

186 *2.7 Delayed-type hypersensitivity (DTH) reaction*

187 The DTH reaction is a method to evaluate the cell-immunity
188 function²². At the first day of intraperitoneal (i.p.) injection of CTX, mice
189 were covered with 20 μ L 5% dinitrofluorobenzene dissolved in acetone–
190 olive oil (acetone: olive oil=1:1) on the shaved belly skin. The second
191 sensitization was made after 5 days and 10 μ L 5% dinitrofluorobenzene
192 was evenly applied to both sides of the right ear of the mouse. After 24 h,

193 the mice were sacrificed and the 8 mm ear patches were removed and
194 weighed. The extent of the DTH reaction was evaluated by the change
195 between the weight of the right and left ear.

196 *2.8 Measurements of serum immunoglobulin (Ig)*

197 The serum was obtained from eyeball blood after centrifugation. The
198 concentrations of IgG and IgM in serum were determined by the ELISA
199 kit according to the instructions of manufacturer.

200 *2.9 Determination of IL-2, IFN- γ and NO*

201 The splenic lymphocytes were incubated (1×10^6 cells/mL) with 20
202 $\mu\text{g/mL}$ ConA for 48 h in 24-well plates in a 37 °C in 5% CO₂ atmosphere.
203 The supernatants were gathered to detect the level of IL-2, IFN- γ and NO
204 according to commercial kits.

205 *2.10 Real time-PCR (RT-PCR) assay*

206 The total RNA was extracted from spleen using the Trizol reagent.
207 The resulting RNA was reverse transcribed using a Hifair™ II 1st Strand
208 cDNA Synthesis SuperMix Kit (Yeasen, China). The RT reaction was
209 performed at 42 °C for 15 min and 85 °C for 2 min to prepare cDNA, which
210 was then stored at -80 °C for use. Real-time PCR was carried out using an
211 LightCycle 480 real-time PCR system and a real-time PCR master mix
212 (SYBR Green) reagent kit (Yeasen, China). Custom-made primers are
213 present in Table 1. The conditions for real-time PCR were 95 °C for 5min,
214 then 40 cycles at 95 °C for 10 s, 60 °C for 30 s, and 95 °C for 15 s, 60 °C

215 for 1 min, 95 °C for 15 s. Relative mRNA expression was calculated by the
216 $2^{-\Delta\Delta CT}$ method.

217 *2.11 Western blot assay*

218 To prepare total protein sample, the spleen homogenates of each
219 group were lysed for 5 min in ice bath and centrifuged (12000g, 30 min) at
220 4 °C. The concentration of protein was determined by BCA method. After
221 boiling for 5min in SDS sample buffer, the proteins were separated by 10%
222 SDS-PAGE, transferred to PVDF membranes and probed with primary
223 antibody against p-JNK (1:2000), JNK (1:1000), p-ERK (1:2000), ERK
224 (1:1000), p-p38 MAPK (1:1000) and p38 MAPK (1:1000, CST,USA)
225 according to the manufacturer's instructions. 5% BSA (prepared in TBST
226 containing 0.1% Tween 20) was used to block the membranes at 4 °C with
227 gentle shaking, overnight. The membranes were incubated with the
228 appropriate second antibodies at room temperature for 1 h. The antigen-
229 antibody complexes were visualized using an ECL kit (Solarbio, Beijing).
230 To quantify protein levels, the protein bands were scanned, and their
231 intensities and areas were analyzed using ImageJ (NIH, USA).

232 *2.12 Statistical analysis*

233 Results were expressed as mean \pm SD. All data were analyzed by one-
234 way ANOVA with Tukey post-test. Significance was defined as $P < 0.05$.

235 **3. Results**

236 *3.1 Characterization of CPO*

237 CPO was brownish yellow and hygroscopic powder. The yield of
238 CPO was 14.3 g/100 g and the sugar content was 92.7%. CPO had no UV
239 absorption at 280 nm, indicating that there was no protein contained in the
240 prepared CPO. As shown in Fig.1, The result of ESI-MS indicated that
241 CPO was mainly composed of saccharides with DP from 1 to 7. Many
242 natural carbohydrates with low degree of polymerization are sweetness,
243 such as maltose, lactose, trehalose, maltulose, isomaltulose (palatinose),
244 lactulose, cellobiulose, melibiulose and fructo-oligosaccharides²³.
245 Therefore, we thought CPO was sweet. In addition, we produced a small
246 amount of CPO using food-grade reagents and found it tasted sweet.

247 *3.2 Effect of CPO on innate immunity in CTX-treated mice*

248 *3.2.1 Spleen and thymus indices*

249 The immune organs indices reflect the immune organ function to a
250 certain extent²⁴. As displayed in Fig.2a, compared with the normal group,
251 spleen and thymus of the model group significantly decreased ($P < 0.01$).
252 In comparison with the model group, the CPO administration (50, 100 and
253 150 mg/kg) remarkably increased the spleen and thymus indices of the
254 laboratory mice (50 mg/kg, $P < 0.05$; 100, 150 mg/kg, $P < 0.01$). These
255 findings suggested that CPO could alleviate the immune organ atrophy
256 caused by CTX to a certain extent.

257 *3.2.2 Phagocytic index*

258 The phagocytosis of monocytes can be assessed by the carbon

259 clearance assay. The faster removal of carbon particles is linked to stronger
260 phagocytosis²⁵. As shown in Fig. 2b, compared with the normal control,
261 the phagocytic index (α) of the model group significantly decreased ($P <$
262 0.01). Treatment with CPO (100 and 150 mg/kg body weight) could
263 significantly enhance the phagocytic index (α) in comparison with model
264 group. The phagocytic activities of CPO100 and 150 even exceeded the
265 normal level, from 4.26 to 5.82 and 5.66. These results indicated that CPO
266 could improve the carbon clearance ability of CTX-treated mice.

267 *3.3 Effect of CPO on adaptive immunity in CTX-treated mice*

268 *3.3.1 The proliferation of splenic lymphocytes*

269 The cell mitogens ConA and LPS can motivate lymphocytes
270 proliferation reactions²⁶. As shown in Fig. 2c, compared with the control
271 group, splenic lymphocytes proliferation was substantially decreased
272 attributing to ConA or LPS stimulation to the CTX-treated mice ($P < 0.01$).
273 In addition, the CPO-treated group significantly upregulated the splenic
274 lymphocytes proliferation induced by ConA or LPS (50 mg/kg, $P < 0.05$;
275 100, 150 mg/kg, $P < 0.01$), especially at the dose of 100 mg/kg body
276 weight.

277 *3.3.2 DTH reaction mediated by T cells*

278 The earlap swelling indicates the strength of DTH reaction, which is
279 mediated by T cells involved in cellular immunity²². As shown in Fig. 2d,
280 compared with the normal group, it showed a significant decrease of earlap

281 swelling in the model group ($P < 0.01$), which indicated that the DTH
282 model induced by DNFB was successfully established. Moreover, CPO
283 treatment could effectively increase earlap swelling in comparison with the
284 model group ($P < 0.01$), which indicated that CPO could reinforce DTH
285 reaction in CTX-treated mice. The results demonstrated that the
286 immunomodulatory activity of CPO might be associated with cellular
287 immunity.

288 3.3.3 *The contents of serum Ig*

289 The serum immunoglobulins are critical markers of humoral
290 immunity²⁷. The serum Ig G and Ig M levels were measured by ELISA to
291 assess the effect of CPO on the humoral immunity of CTX-treated mice.
292 As the Fig. 3 showed, the concentration of Ig M and Ig G of model group
293 decreased remarkably ($P < 0.01$), while CPO treatment group (100 and 150
294 mg/kg) had a significantly increase of the levels of Ig M and Ig G ($P <$
295 0.05). Thus, the immunomodulatory effects of CPO might be related to
296 humoral immunity in CTX-treated mice.

297 3.4 *Effect of CPO on cytokines and NO secretion in CTX-treated mice*

298 In order to further demonstrate the immunomodulatory activity of
299 CPO, the secretion of cytokines (IL-2, IFN- γ) and NO produced by
300 splenic lymphocytes were measured. As shown in Fig. 4, IL-2, IFN- γ and
301 NO levels in the supernatants of splenic lymphocytes cultures were
302 significantly decrease in CTX-treated mice compared with the normal

303 group ($P < 0.01$). The concentrations of IL-2, IFN- γ and NO in CPO
304 treatment groups increased markedly in comparison with the model group.
305 At the doses of 50, 100 and 150 mg/kg, CPO treatment significantly
306 increased the IL-2 concentration by 3.5-, 4.5- and 4.2-fold of the model
307 group, respectively. Correspondingly, when processing with CPO (100 and
308 150 mg/kg), the amount of NO secretion significantly increased, which was
309 5.4- and 4.2-fold of the model group, respectively. IFN- γ production could
310 be enhanced after CPO administration (100 mg/kg). Therefore, CPO could
311 synergize with Con A to stimulate splenic lymphocytes, resulting in
312 increased levels of IL-2, IFN- γ and NO.

313 *3.5 Effect of CPO on gene expression in CTX-treated mice*

314 As shown in Fig. 5, RT-PCR analysis displayed that CTX-induced
315 mice had lower expression of related genes than that in the normal group
316 ($P < 0.01$). CPO treatment remarkably increased the related gene
317 expression in comparison with the model group, which was consonant with
318 the levels of IL-2, IFN- γ and NO. When the dosage of CPO was 100 mg /
319 kg, the mRNA expression levels of iNOS, IL-2 and IFN- γ were 3.4, 5.1,
320 and 4.2 times that of the model group, respectively. In general, CPO could
321 promote the secretion of cytokines (IL-2 and IFN- γ) and NO by enhancing
322 the gene expression of IL-2, IFN- γ , and iNOS in CTX-treated mice.

323 *3.6 Effect of CPO on protein expression in CTX-treated mice*

324 MAPK is a family of serine / threonine-specific protein kinase which

325 is involved in regulating many cell life activities²⁵. Furthermore, the
326 activation of MAPKs affects the cellular response to cytokines and
327 expression of related genes²⁸. Western blot analysis was used to analyze
328 MAPKs protein expression, including phosphorylated JNK,
329 phosphorylated ERK, and phosphorylated p38. As shown in Fig. 6,
330 phosphorylation of JNK, ERK and p38 decreased significantly in CTX-
331 treated mice in comparison with the normal group ($P < 0.01$). Nevertheless,
332 compared to the model group, the protein expression of phosphorylated
333 p38, phosphorylated ERK1/2 and phosphorylated JNK in CPO treatment
334 were significantly increased. After dosing with 50 mg/kg of CPO, the ratio
335 of the protein contents of phosphorylated p38/p38 increased from 0.16
336 (model group) to 0.58. After treated with 100 mg/kg of CPO, the ratio of
337 the protein contents of phosphorylated ERK/ERK increased from 0.40
338 (model group) to 2.32. The administration of 150 mg/kg CPO could
339 increase the ratio of the protein contents of phosphorylated JNK/JNK from
340 0.50 (model group) to 6.26. To sum up, CPO might improve CTX-induced
341 immune suppression by activating MAPKs signaling pathway.

342

343 4. Discussion

344 CPO was obtained from *C.pilosula* by water extraction and alcohol
345 precipitation combined with column chromatography. The yield of CPO
346 was as high as 14.3% and the sugar content was 92.7%. It has been said the

347 sweeter the *C.pilosula* tastes, the better. Therefore, we focused on CPO and
348 studied its immunomodulatory effect on CTX-induced immunosuppressed
349 mice.

350 CTX is an alkylating agent and an important chemotherapeutic drug
351 for the treatment of malignant tumors. However, CTX can damage the
352 DNA of normal cells and cause immunosuppression²⁹. In our research,
353 CTX was used to build an immunodeficiency model in mice. Not
354 surprisingly, the results showed that CTX could reduce the immune organs
355 indices, arrest proliferation of splenic lymphocytes, decrease secretion of
356 cytokines and NO and inhibit DNFB-induced DTH reaction, which
357 indicated that the immunosuppression model induced by CTX was
358 established successfully.

359 The spleen and thymus are important immune organs and the immune
360 organs indices indicated the function of innate immunity to a certain
361 extent³⁰. The treatment of CPO could remarkably increase the thymus and
362 spleen indices in CTX-treated mice. Meanwhile, macrophages can perform
363 phagocytosis through the innate immune response³¹. The increase in
364 phagocytic index (α) of CTX-treated mice treated with CPO (100 and 150
365 mg/kg) indicated that CPO could enhance phagocytic ability of
366 macrophages.

367 Adaptive immune system, including cell and humoral immune
368 responses, can protect the body from the invasion of specific pathogens.

369 Lymphocyte proliferation plays a critical role in activating process of
370 adaptive immune³². Lymphocytes proliferation induced by mitogen ConA
371 or LPS has been widely used as a method to evaluate T or B lymphocyte
372 activity because of its high sensitivity. The present results indicated that
373 CPO (50, 100 and 150 mg/ kg) could enhance ConA- and LPS-induced
374 splenic lymphocytes proliferation. DNFB-induced DTH reaction is a type
375 of cellular immunity mediated by T lymphocytes, the character of which is
376 the large aggregation of non-specific inflammatory cells³³. CPO treatment
377 could enhance DTH reaction by increasing earlap swelling in CTX-treated
378 mice. This result indicated that CPO might play a role in assisting cellular
379 immune response. Immunoglobulins play an important role in humoral
380 immunity and can recognize and neutralize foreign substances²⁷. In this
381 study, it is observed that CPO (100 and 150 mg/kg) showed significant
382 increments in Ig G and Ig M contents in comparison with the model group.
383 Thus, CPO might exert immunomodulatory effects through humoral
384 immunity in CTX-treated mice.

385 Cytokines play vital roles in the immune system, which are involved
386 in the preservation or restoration of homeostasis via coordination of
387 lymphoid cells, inflammatory cells, and hematopoietic cells³⁴. IFN- γ and
388 IL-2 are primary immunity-related cytokines. IFN- γ could induce the
389 generation of T cells, activate macrophages, regulate crossly Th1 and Th2
390 cells³⁵. IL-2 is a pleiotropic cytokine that promotes T cell growth, enhances

391 NK cell lytic activity, and induces the differentiation of Treg cells³⁶. NO is
392 an important signaling medium in organisms involved in many biological
393 functions, such as host defense and neural transmission³¹. Our results
394 showed that CPO treatment could increase the levels of IFN- γ , IL-2 and
395 NO in the supernatants of splenic lymphocytes cultures in CTX-treated
396 mice, which is in accordance with the mRNA expression of IFN- γ , IL-2
397 and iNOS.

398 MAPK is a family of serine / threonine protein kinases, including JNK,
399 ERK1/2 and p38³⁷. MAPKs signaling pathways regulate immune response
400 by regulating the compound and releasing of cytokines and the related
401 mRNA expression. For example, glycoprotein from *Dioscorea opposita*
402 Thunb can stimulate macrophages to secrete IL-6, TNF- α and NO via
403 MAPKs and NF- κ B pathways²¹. In this study, CPO could enhance the
404 protein expression of p-p38, p-JNK and P-ERK1/2, which indicated that
405 CPO might exhibit immunomodulatory activities through up-regulating
406 various transcription factors in MAPKs signaling pathway. These findings
407 are meaningful to understand the potential immunomodulatory molecular
408 mechanisms of CPO . The possible mechanism was shown in Fig 7.

409 The results showed that CPO had good immunomodulatory activity,
410 which had been firstly proved the scientific of the saying “ the sweeter the
411 *C.pilosula* tastes, the better it is ”. We demonstrated that not only
412 polysaccharides but also oligosaccharides were important active ingredient

413 in *C.pilosula*. Compared with polysaccharide fraction, the separation and
414 purification of oligosaccharides were simpler, the water solubility was
415 better, bioavailability was higher and quality control was easier.

416 **5. Conclusion**

417 To sum up, our results firstly showed that oligosaccharides from
418 *Codonopsis pilosula* were important active components and had protective
419 effects against immunosuppression induced by CTX. These findings
420 provided the basis for the development of CPO as a functional food or drug
421 with immunomodulatory activity. Meanwhile, it was the first time to
422 clarify that the quality of *C.pilosula* might be closely tied to its sweet
423 oligosaccharides. However, although the sugar content of CPO is as high
424 as 92.7%, it is still a mixture of glycans and it needs further investigation
425 about which glycans play the most important role.

426 **Conflicts of interest**

427 The authors declare no conflicts of interest.

428 **Acknowledgment**

429 The authors acknowledge the National Key Research and
430 Development Program of China (2018YFC1706300, 2018YFC17063003),
431 Special funds for Innovation and Guidance of Gansu (2017ZX-02), the
432 Science-Technology plan Project from Lanzhou Science and Technology
433 Bureau (2017-RC115), the Key R&D Project of Gansu Provincial Science
434 and Technology Department (17ZD2FA009), the Key Project of the

435 Fundamental Research Funds for the Central Universities (Izujbky-2018-
436 k13, Izujbky-2017-205).

437

438 **Notes and references**

- 439 1 Ross, R. G., Selvasubramanian, S. & Jayasundar, S,
440 Immunomodulatory Activity of Punica Granatum in Rabbits--A
441 Preliminary Study. *J. Ethnopharmacol.*, **78**, 85–87 (2001).
- 442 2 J. W. Kim, J. S. Choi, D. J. Seol, J. J. Choung and S. K. Ku,
443 Immunomodulatory Effects of Kuseonwangdoga-Based Mixed
444 Herbal Formula Extracts on a Cyclophosphamide-Induced
445 Immunosuppression Mouse Model, *Evidence-based Complement.*
446 *Altern. Med.*, DOI:10.1155/2018/6017412.
- 447 3 X. Zhou, H. Shi, G. Jiang, Y. Zhou and J. Xu, Antitumor activities of
448 ginseng polysaccharide in C57BL/6 mice with Lewis lung carcinoma,
449 *Tumor Biol.*, 2014, **35**, 12561–12566.
- 450 4 T. Zhao, G. Mao, R. Mao, Y. Zou, D. Zheng, W. Feng, Y. Ren, W.
451 Wang, W. Zheng, J. Song, Y. Chen, L. Yang and X. Wu, Antitumor
452 and immunomodulatory activity of a water-soluble low molecular
453 weight polysaccharide from Schisandra chinensis (Turcz.) Baill,
454 *Food Chem. Toxicol.*, 2013, **55**, 609–616.
- 455 5 P. A. Ayeka, Y. Bian, P. G. Mwitari, X. Chu, Y. Zhang, R.
456 Uzayisenga and E. O. Otachi, Immunomodulatory and anticancer

- 457 potential of Gan cao (*Glycyrrhiza uralensis* Fisch.) polysaccharides
458 by CT-26 colon carcinoma cell growth inhibition and cytokine IL-7
459 upregulation in vitro, *BMC Complement. Altern. Med.*, 2016, **16**, 1–
460 8.
- 461 6 B. Yang, B. Xiao and T. Sun, Antitumor and immunomodulatory
462 activity of *Astragalus membranaceus* polysaccharides in H22 tumor-
463 bearing mice, *Int. J. Biol. Macromol.*, 2013, **62**, 287–290.
- 464 7 H. Liu, J. Ma, F. Gong, F. Wei, X. Zhang and H. Wu, Structural
465 characterisation and immunomodulatory effects of polysaccharides
466 isolated from *Dendrobium aphyllum*, *Int. J. Food Sci. Technol.*, 2018,
467 **53**, 1185–1194.
- 468 8 M. Zou, Y. Chen, D. Sun-Waterhouse, Y. Zhang and F. Li,
469 Immunomodulatory acidic polysaccharides from *Zizyphus jujuba* cv.
470 Huizao: Insights into their chemical characteristics and modes of
471 action, *Food Chem.*, 2018, **258**, 35–42.
- 472 9 J. Du, X. Chen, C. Wang and H. Sun, Pathway analysis of global gene
473 expression change in dendritic cells induced by the polysaccharide
474 from the roots of *Actinidia eriantha*, *J. Ethnopharmacol.*, 2018, **214**,
475 141–152.
- 476 10 R. Bai, W. Li, Y. Li, M. Ma, Y. Wang, J. Zhang and F. Hu,
477 Cytotoxicity of two water-soluble polysaccharides from *Codonopsis*
478 *pilosula* Nannf. var. *modesta* (Nannf.) L.T.Shen against human

- 479 hepatocellular carcinoma HepG2 cells and its mechanism, *Int. J. Biol.*
480 *Macromol.*, 2018, **120**, 1544–1550.
- 481 11 Q. L. Sun, Y. X. Li, Y. S. Cui, S. L. Jiang, C. X. Dong and J. Du,
482 Structural characterization of three polysaccharides from the roots of
483 *Codonopsis pilosula* and their immunomodulatory effects on
484 RAW264.7 macrophages, *Int. J. Biol. Macromol.*, 2019, **130**, 556–
485 563.
- 486 12 S. Yongxu and L. Jicheng, Structural characterization of a water-
487 soluble polysaccharide from the Roots of *Codonopsis pilosula* and its
488 immunity activity, *Int. J. Biol. Macromol.*, 2008, **43**, 279–282.
- 489 13 P. Zhang, L. Hu, R. Bai, X. Zheng, Y. Ma, X. Gao, B. Sun and F. Hu,
490 Structural characterization of a pectic polysaccharide from
491 *Codonopsis pilosula* and its immunomodulatory activities in vivo and
492 in vitro, *Int. J. Biol. Macromol.*, 2017, **104**, 1359–1369.
- 493 14 X. Deng, Y. Fu, S. Luo, X. Luo, Q. Wang, M. Hu, F. Ma, C. W. Ma
494 and L. Zhou, Polysaccharide from *Radix Codonopsis* has beneficial
495 effects on the maintenance of T-cell balance in mice, *Biomed.*
496 *Pharmacother.*, 2019, **112**, 0–6.
- 497 15 Y. P. Fu, B. Feng, Z. K. Zhu, X. Feng, S. F. Chen, L. X. Li, Z. Q.
498 Yin, C. Huang, X. F. Chen, B. Z. Zhang, R. Y. Jia, X. Song, C. Lv,
499 G. Z. Yue, G. Ye, X. X. Liang, C. L. He, L. Z. Yin and Y. F. Zou,
500 The Polysaccharides from *Codonopsis pilosula* Modulates the

- 501 Immunity and Intestinal Microbiota of Cyclophosphamide-Treated
502 Immunosuppressed Mice, *Molecules*, 2018, 23, 1801-1813..
- 503 16 Y. Zou, X. Chen, K. Egil, F. Rise, H. Barsett, K. Tvette, T. Einar and
504 B. Smestad, Structural features and complement fixing activity of
505 polysaccharides from *Codonopsis pilosula* Nannf. var. *modesta* L.
506 T. Shen roots, *Carbohydr. Polym.*, 2014, **113**, 420–429.
- 507 17 W. Liu, X. Lv, W. Huang, W. Yao and X. Gao, Characterization and
508 hypoglycemic effect of a neutral polysaccharide extracted from the
509 residue of *Codonopsis Pilosula*, *Carbohydr. Polym.*, 2018, **197**, 215–
510 226.
- 511 18 Z. Li, L. Zhu, H. Zhang, J. Yang, J. Zhao, D. Du, J. Meng, F. Yang,
512 Y. Zhao and J. Sun, Protective effect of a polysaccharide from stem
513 of *Codonopsis pilosula* against renal ischemia/reperfusion injury in
514 rats, *Carbohydr. Polym.*, 2012, **90**, 1739–1743.
- 515 19 X. F. Zhong, Y. B. Zhang, G. D. Huang, Y. Z. Ouyang, D. J. Liao, J.
516 W. Peng and W. Z. Huang, Proteomic analysis of stachyose
517 contribution to the growth of: *Lactobacillus acidophilus* CICC22162,
518 *Food Funct.*, 2018, **9**, 2979–2988.
- 519 20 G. Xu, W. Xing, T. Li, Z. Ma, C. Liu, N. Jiang and L. Luo, Effects
520 of dietary raffinose on growth, non-specific immunity, intestinal
521 morphology and microbiome of juvenile hybrid sturgeon (*Acipenser*
522 *baeri* Brandt ♀ × *A. schrenckii* Brandt ♂), *Fish Shellfish Immunol.*,

- 523 2018, **72**, 237–246.
- 524 21 X. Niu, Z. He, W. Li, X. Wang, W. Zhi, F. Liu and L. Qi,
525 Immunomodulatory Activity of the Glycoprotein Isolated from the
526 Chinese Yam (*Dioscorea opposita* Thunb), *Phyther. Res.*, 2017, **31**,
527 1557–1563.
- 528 22 H. Wang, S. Yang, Y. Wang, T. Jiang, S. Li and Z. Lv,
529 Immunoenhancement effects of glycosaminoglycan from
530 *Apostichopus japonicus*: In vitro and in cyclophosphamide-induced
531 immunosuppressed mice studies, *Mar. Drugs*, 2017, **15**, 347-361..
- 532 23 C. Belloir, F. Neiers and L. Briand, Sweeteners and sweetness
533 enhancers, *Curr. Opin. Clin. Nutr. Metab. Care*, 2017, **20**, 279–285.
- 534 24 X. Sun, N. Liu, Z. Wu, Y. Feng and X. Meng, Anti-Tumor Activity
535 of a Polysaccharide from Blueberry, *Molecules*, 2015, **20**, 3841–
536 3853.
- 537 25 Q. Li, G. Chen, H. Chen, W. Zhang, Y. Ding, P. Yu, T. Zhao, G.
538 Mao, W. Feng, L. Yang and X. Wu, Se-enriched *G. frondosa*
539 polysaccharide protects against immunosuppression in
540 cyclophosphamide-induced mice via MAPKs signal transduction
541 pathway, *Carbohydr. Polym.*, 2018, **196**, 445–456.
- 542 26 H. Wang, T. Gao, Y. Du, H. Yang, L. Wei, H. Bi and W. Ni,
543 Anticancer and immunostimulating activities of a novel
544 homogalacturonan from *Hippophae rhamnoides* L. berry, *Carbohydr.*

- 545 *Polym.*, 2015, **131**, 288–296.
- 546 27 F. Meng, P. Xu, X. Wang, Y. Huang, L. Wu, Y. Chen, L. Teng and
547 D. Wang, Investigation on the immunomodulatory activities of
548 *Sarcodon imbricatus* extracts in a cyclophosphamide (CTX)-induced
549 immunosuppressed mouse model, *Saudi Pharm. J.*, 2017, **25**,
550 460–463.
- 551 28 C. Y. Shen, W. L. Zhang and J. G. Jiang, Immune-enhancing activity
552 of polysaccharides from *Hibiscus sabdariffa* Linn. via MAPK and
553 NF- κ B signaling pathways in RAW264.7 cells, *J. Funct. Foods*,
554 2017, **34**, 118–129.
- 555 29 Y. Zhou, X. Chen, R. Yi, G. Li, P. Sun, Y. Qian and X. Zhao,
556 Immunomodulatory effect of tremella polysaccharides against
557 cyclophosphamide-induced immunosuppression in mice, *Molecules*,
558 2018, **23**, 1–12.
- 559 30 G. Bin Ding, R. H. Nie, L. H. Lv, G. Q. Wei and L. Q. Zhao,
560 Preparation and biological evaluation of a novel selenium-containing
561 exopolysaccharide from *Rhizobium* sp. N613, *Carbohydr. Polym.*,
562 2014, **109**, 28–34.
- 563 31 F. Wu, C. Zhou, D. Zhou, S. Ou, Z. Liu and H. Huang, Immune-
564 enhancing activities of chondroitin sulfate in murine macrophage
565 RAW 264.7 cells, *Carbohydr. Polym.*, 2018, **198**, 611–619.
- 566 32 Y. Zheng, W. D. Wang and Y. Li, Antitumor and immunomodulatory

- 567 activity of polysaccharide isolated from *Trametes orientalis*,
568 *Carbohydr. Polym.*, 2015, **131**, 248–254.
- 569 33 X. Xie, G. Zou and C. Li, Antitumor and immunomodulatory
570 activities of a water-soluble polysaccharide from *Chaenomeles*
571 *speciosa*, *Carbohydr. Polym.*, 2015, **132**, 323–329.
- 572 34 B. Wei, R. Zhang, J. Zhai, J. Zhu, F. Yang, D. Yue, X. Liu, C. Lu
573 and X. Sun, Suppression of Th17 Cell Response in the Alleviation of
574 Dextran Sulfate Sodium-Induced Colitis by *Ganoderma lucidum*
575 Polysaccharides, *J. Immunol. Res.*, 2018, **2018**, 1–10.
- 576 35 Z. Cai, W. Li, H. Wang, W. Yan, Y. Zhou, G. Wang, J. Cui and F.
577 Wang, Anti-tumor and immunomodulating activities of a
578 polysaccharide from the root of *Sanguisorba officinalis* L, *Int. J. Biol.*
579 *Macromol.*, 2012, **51**, 484–488.
- 580 36 N. Liu, Z. Dong, X. Zhu, H. Xu and Z. Zhao, Characterization and
581 protective effect of *Polygonatum sibiricum* polysaccharide against
582 cyclophosphamide-induced immunosuppression in Balb/c mice, *Int.*
583 *J. Biol. Macromol.*, 2018, **107**, 796–802.
- 584 37 S. Gurusmatika, K. Nishi, E. Harmayani, Y. Pranoto and T. Sugahara,
585 Immunomodulatory Activity of Octenyl Succinic Anhydride
586 Modified Porang (*Amorphophallus oncophyllus*) Glucomannan on
587 Mouse Macrophage-Like J774.1 Cells and Mouse Primary Peritoneal
588 Macrophages, *Molecules*, 2017, **22**, 1187-1200.

589

590

591 **Figure captions**

592 Fig. 1: ESI-MS spectrum of CPO.

593 Fig. 2: Effects of CPO on immune organ index (a), phagocytic index (b),
594 ConA- and LPS-induced splenocyte proliferation (c), ear swelling in DTH
595 reaction (d) in CTX-treated mice. NC, normal control group; MC, CTX-
596 induced mice group; XXT, positive control group (thymosin, 10mg/kg bw);
597 CPO, oligosaccharides from *Codonopsis pilosula*(50,100,150mg/kg bw).
598 Values are given as means \pm S.D. *P < 0.05, **P < 0.01 vs. Normal group;
599 #P < 0.05, ##P < 0.01 vs. Model control.

600 Fig. 3: Effect of CPO on IgG (a) and IgM (b) contents in serum of CTX-
601 treated mice. NC, normal control group; MC, CTX- induced mice group;
602 XXT, positive control group (thymosin, 10mg/kg bw); CPO,
603 oligosaccharides from *Codonopsis pilosula*(50,100,150mg/kg bw). Values
604 are given as means \pm S.D. *P < 0.05, **P < 0.01 vs. Normal group; #P <
605 0.05, ##P < 0.01 vs. Model control.

606 Fig. 4: Effect of CPO on IL-2 (a), IFN- γ (b) and NO (c) levels in CTX-
607 treated mice. NC, normal control group; MC, CTX- induced mice group;
608 XXT, positive control group (thymosin, 10mg/kg bw); CPO,
609 oligosaccharides from *Codonopsis pilosula*(50,100,150mg/kg bw). Values
610 are given as means \pm S.D. *P < 0.05, **P < 0.01 vs. Normal group; #P <

611 0.05, ##P < 0.01 vs. Model control.

612 Fig. 5: Effect of CPO on mRNA expression levels of IL-2 (a), IFN- γ (b)
613 and iNOS (c) in spleens of CTX-treated mice. NC, normal control group;
614 MC, CTX- induced mice group; XXT, positive control group (thymosin,
615 10mg/kg bw); CPO, oligosaccharides from *Codonopsis pilosula*
616 (50,100,150mg/kg bw). Values are given as means \pm S.D. *P < 0.05, **P <
617 0.01 vs. Normal group; #P < 0.05, ##P < 0.01 vs. Model control.

618 Fig. 6: Effect of CPO on the phosphorylation of mitogen activated protein
619 kinase (MAPK) in spleens of CTX-treated mice. (a) The proteins isolated
620 from splenocytes were analyzed by western blot with anti-p-ERK, anti-p-
621 JNK, anti-p-p38 antibodies. ERK, p38 and JNK were used as loading
622 controls. (b) Levels of p-p38/p38, (c) Levels of p-ERK/ERK and (d) Levels
623 of p-JNK/JNK. Histogram represents quantification of protein expression
624 levels using ImageJ software. NC, normal control group; MC, CTX-
625 induced mice group; XXT, positive control group (thymosin, 10mg/kg bw);
626 CPO, oligosaccharides from *Codonopsis pilosula* (50,100,150mg/kg bw).
627 Values are given as means \pm S.D. *P < 0.05, **P < 0.01 vs. Normal group;
628 #P < 0.05, ##P < 0.01 vs. Model control.

629 Fig. 7: Possible mechanisms by which CPO activate splenic lymphocytes.

630

631

632

633

634

635 **Table**

636

637

638

639

640

641

Table 1. Primers used for qPCR analysis of genes

Genes	Forward primer (5'-3')	Reverse primer (5'-3')
β -actin	GTGCTATGTTGCTCTAGACTTCG	ATGCCACAGGATTCCATACC
iNOS	CAAGCTGAACTTGAGCGAGGA	TTTACTCAGTGCCAGAAGCTGGA
IL-2	CCCAGGATGCTCACCTTCA	CCGCAGAGGTCCAAGTTCA
IFN- γ	CGGCACAGTCATTGAAAGCCTA	GTTGCTGATGGCCTGATTGTC

642

643

644

645

646

647

648

649

650

651

652


653

654

655

656

657 Fig. 1



658

659

660

661

662

663

664

665

666

667


668

669

670

671

672 Fig. 2



673

674

675

676

677

678

679

680


681

682

683

684

685 Fig. 3



686

687

688

689

690

691

692

693


694

695

696

697

698 Fig. 4



699

700

701

702

703

704

705

706


707

708

709

710

711 Fig. 5



712

713

714

715

716

717

718


719

720

721

722

723 Fig. 6



724

725

726

727

728

729

730


731

732

733

734 Fig. 7

735



Food & Function Accepted Manuscript

736

737

738

739

740

741

742

743

744

745

746

747

748

The oligosaccharides are the main components of *C.pilosula* and exert excellent immunomodulatory activities.

